ETVr substitutions (in addition to LVDr substitutions rtM204V/ I ± rtL180M) were observed at baseline in isolates from 10/ 187 (5%) lamivudine-refractory patients treated with entecavir and monitored for resistance, indicating that prior lamivudine treatment can select these resistance substitutions and that they can exist at a low frequency before entecavir treatment.